You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR PRIVIGEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PRIVIGEN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00750867 ↗ Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins Completed University of Massachusetts, Worcester Phase 2 2008-06-01 Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease. Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity. This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
NCT01561755 ↗ A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy Terminated CSL Behring Phase 4 2012-02-01 The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT01561755 ↗ A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy Terminated David M. Simpson Phase 4 2012-02-01 The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT02111161 ↗ Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed CSL Behring Phase 2 2014-04-01 The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PRIVIGEN

Condition Name

Condition Name for PRIVIGEN
Intervention Trials
Kidney Transplantation 2
Scleroderma 1
Miscarriage 1
Systemic Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PRIVIGEN
Intervention Trials
Sclerosis 2
Scleroderma, Diffuse 1
Fournier Gangrene 1
Mucocutaneous Lymph Node Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PRIVIGEN

Trials by Country

Trials by Country for PRIVIGEN
Location Trials
United States 5
France 2
Denmark 2
Canada 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PRIVIGEN
Location Trials
Illinois 3
New York 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PRIVIGEN

Clinical Trial Phase

Clinical Trial Phase for PRIVIGEN
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PRIVIGEN
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Terminated 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PRIVIGEN

Sponsor Name

Sponsor Name for PRIVIGEN
Sponsor Trials
CSL Behring 5
Northwestern University 3
Assistance Publique - Hôpitaux de Paris 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PRIVIGEN
Sponsor Trials
Other 29
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.